Becton, Dickinson and Company $BDX Shares Acquired by Arlington Partners LLC

Key Points

• Arlington Partners LLC increased its stake in Becton, Dickinson and Company by 42.2% during the second quarter, now holding shares worth approximately $4.41 million.
• Institutional investors own 86.97% of Becton, Dickinson and Company's stock, with notable transactions from GQG Partners LLC and Vanguard Group Inc.
• Becton, Dickinson and Company reported quarterly earnings of $3.68 EPS, exceeding expectations, and declared a quarterly dividend of $1.04 per share.

Arlington Partners LLC grew its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 42.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,578 shares of the medical instruments supplier's stock after purchasing an additional 7,591 shares during the period. Arlington Partners LLC's holdings in Becton, Dickinson and Company were worth $4,406,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Caitlin John LLC boosted its position in Becton, Dickinson and Company by 29.4% during the second quarter. Caitlin John LLC now owns 1,874 shares of the medical instruments supplier's stock valued at $323,000 after acquiring an additional 426 shares during the last quarter. S.A. Mason LLC grew its stake in shares of Becton, Dickinson and Company by 6.4% in the 2nd quarter. S.A. Mason LLC now owns 1,504 shares of the medical instruments supplier's stock valued at $259,000 after buying an additional 90 shares during the period. Ridgewood Investments LLC grew its stake in Becton, Dickinson and Company by 10.0% in the second quarter. Ridgewood Investments LLC now owns 2,348 shares of the medical instruments supplier's stock valued at $404,000 after acquiring an additional 213 shares during the period. Farmers & Merchants Investments Inc. lifted its holdings in shares of Becton, Dickinson and Company by 2.9% in the 2nd quarter. Farmers & Merchants Investments Inc. now owns 22,630 shares of the medical instruments supplier's stock worth $3,898,000 after purchasing an additional 641 shares in the last quarter. Finally, Abacus Wealth Partners LLC increased its stake in Becton, Dickinson and Company by 16.4% during the 2nd quarter. Abacus Wealth Partners LLC now owns 1,350 shares of the medical instruments supplier's stock valued at $233,000 after purchasing an additional 190 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Barclays lowered their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Piper Sandler restated a "neutral" rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Finally, Argus boosted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Four research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $213.30.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,965 shares of company stock valued at $551,536. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX stock traded down $0.30 during trading hours on Monday, hitting $186.74. The stock had a trading volume of 1,227,724 shares, compared to its average volume of 1,592,393. The stock's 50-day moving average price is $187.84 and its two-hundred day moving average price is $189.61. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The stock has a market capitalization of $53.53 billion, a price-to-earnings ratio of 33.59, a PEG ratio of 1.51 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same period last year, the business posted $3.50 EPS. Becton, Dickinson and Company's quarterly revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.